Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ivermectin, quantity: 3 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; butylated hydroxyanisole; citric acid - stromectol (ivermectin) is indicated for the treatment of: a) onchocerciasis and intestinal strongyloidiasis (anguillulosis). b) crusted scabies in conjunction with topical therapy c) human sarcoptic scabies when prior topical treatment has failed or is contraindicated. treatment is only justified when the diagnosis of scabies has been established clinically and /or by parasitological examination. without formal diagnosis, treatment is not justified in case of pruritus alone.?

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

substipharm - ivermectin 3 mg - tablet - 3 mg - ivermectin 3 mg - ivermectin

United States - English - NLM (National Library of Medicine)

central texas community health centers - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin 3 mg - ivermectin is indicated for the treatment of the following infections: ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite strongyloides stercoralis . this indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (see clinical pharmacology, clinical studies). ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite onchocerca volvulus . this indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of west africa. the comparative studies used diethylcarbamazine citrate (dec-c). note: ivermectin has no activity against adult onchocerca volvulus parasites. the adult parasites reside in subcutaneous nodules which are infrequently palpable. surgical excision of these nodules (nodulectomy) may b

United States - English - NLM (National Library of Medicine)

durvet, inc. - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin 5 mg in 5 l - indications ivermectin (ivermectin topical solution) pour-on applied at the recommended dose level of 500 mcg/kg is indicated for the effective treatment and control of these parasites. gastrointestinal roundworms ostertagia ostertagi                (adults and l4 ) (including inhibited state) haemonchus placei                (adults and l4 ) trichostrongylus axei              (adults and l4 ) t. colubriformis                      (adults and l4 ) cooperia oncophora                (adults and l4 ) cooperia punctata                  (adults and l4 ) cooperia surnabada                (adults and l4 ) strongyloides papillosus         (adults) oesophagostomum radiatum   (adults and l4 ) trichuris spp.                         (adults) lungworms dictyocaulus viviparus             (adults and l4 ) cattle grubs                         (parasitic stages) hypoderma bovis h. lineatum mites sarcoptes scabiei var. bovis lice linognathus vituli haematopinus eurysternus damalinia bovis solenopotes capillatus horn flies haem

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ivermectin 3mg - tablet - 3 mg - active: ivermectin 3mg excipient: butylated hydroxyanisole citric acid magnesium stearate microcrystalline cellulose starch - · treatment of intestinal strongyloidiasis (anguillulosis). · treatment of proven suspected microfilaraemia in patients with lymphatic filariasis caused by wuchereria bancrofti. · treatment of human sarcoptic scabies after prior treatment has failed. treatment is justified when the diagnosis of scabies has been established clinically and/or by parasitological examination. without formal diagnosis, treatment is not justified in case of pruritus.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin 3 mg - stromectol is indicated for the treatment of the following infections: strongyloidiasis of the intestinal tract . stromectol is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite strongyloides stercoralis . this indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (see clinical pharmacology, clinical studies.) onchocerciasis . stromectol is indicated for the treatment of onchocerciasis due to the nematode parasite onchocerca volvulus . this indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of west africa. the comparative studies used diethylcarbamazine citrate (dec-c). note: stromectol has no activity against adult onchocerca volvulus parasites. the adult parasites reside in subcutaneous nodules which are infrequently palpable. surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. stromectol is contraindicated in patients who are hypersensitive to any component of this product.

United States - English - NLM (National Library of Medicine)

durvet - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin 5 mg in 1 ml - ivermectin pour-on for cattle applied at the recommended dose level of 500 mcg/kg is indicated for the effective treatment and control of these parasites. gastrointestinal roundworms ostertagia ostertagi (including inhibited stage)        (adults and l4 ) haemonchus placei                                                 (adults and l4 ) trichostrongylus axei                                              (adults and l4 ) t. colubriformis                                                       (adults and l4 ) cooperia oncophora                                                 (adults and l4 ) cooperia punctata                                                  (adults and l4 ) cooperia surnabada                                                 (adults and l4 ) strongyloides papillosus                                                      (adults) oesophagostomum radiatum                                  (adults and l4 ) trichuris spp.                                                                    (adults) lungworms dictyocaulus viviparus                                              (adults and l4 ) cattle grubs                                                       (parasitic stages) hypoderma bovis h. lineatum mites sarcoptes scabiei var. bovis lice linognathus vituli haematopinus eurystemus damalinia bovis solenopotes capillatus horn flies haematobia irritans persistent activity ivermectin pour-on for cattle has been proved to effectively control infections and to protect cattle from re-infection with: oesophagostomum radiatum and dictyocaulus viviparous for 28 days after treatment; cooperia punctata and trichostrongylus axei for 21 days after treatment; ostertagia ostertagi , haemonchus placei , cooperia oncophora and cooperia surnabada for 14 days after treatment; damalinia bovis for 56 days after treatment. treatment of cattle for horn flies ivermectin pour-on for cattle controls horn flies (haematobia irritans ) for up to 28 days after dosing. for best results ivermectin pour-on for cattle should be part of a parasite control program for both internal and external parasites based on the epidemiology of these parasites. consult your veterinarian or an entomologist for the most effective timing of applications. manufactured for: durvet inc. blue springs, missouri 64014 www.durvet.com

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. none. risk summary the available data on the use of ivermectin, including ivermectin cream, in pregnant women are insufficient to establish a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, ivermectin induced adverse developmental outcomes when orally administered to pregnant rats and rabbits during the period of organogenesis at doses 1909 or 354 times the maximum recommended human dose (mrhd), respectively. these orally administered doses were maternally toxic to pregnant rats and rabbits. in a pre-and postnatal developmental study in rats, neonatal toxicity and adverse effects on behavioral development were observed when ivermectin was orally administered to pregnant females during gestation and lactation (see data ). the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - ivermectin (unii: 8883yp2r6d) (ivermectin - unii:8883yp2r6d) - ivermectin cream is indicated for the treatment of inflammatory lesions of rosacea. none. there are no adequate and well-controlled studies in pregnant women. ivermectin cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. note: the animal multiples of human exposure calculations were based on auc comparisons. the maximum topical human dose (mthd) of ivermectin cream is 1 g applied once daily. risk summary the available data on the use of ivermectin, including ivermectin cream, in pregnant women are insufficient to establish a drug- associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, ivermectin induced adverse developmental outcomes when orally administered to pregnant rats and rabbits during the period of organogenesis at doses 1909 or 354 times the maximum recommended human dose (mrhd), respectively. these orally administered doses were maternally toxic to pregnant rats and rabbi

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - ivermectin - tablet - 3 mg - ivermectin 3 mg